Emcure Pharmaceuticals Limited — Updates, 16-07-2025: Press Release

Emcure Pharmaceuticals has announced an exclusive distribution and promotion partnership with Sanofi India for Sanofi's oral anti-diabetic (OAD) drugs in India, including key brands like Amaryl® and Cetapin®. While Sanofi will continue manufacturing, Emcure will leverage its extensive distribution network to expand reach to healthcare professionals and patients nationwide. This strategic collaboration significantly strengthens Emcure's existing diabetes portfolio, enhancing its market presence and improving patient access to critical therapies for the millions affected by diabetes in India. This move signals Emcure's focus on expanding its therapeutic offerings and market footprint.